HR+HER2- breast cancer
Conditions
Interventions
Neoadjuvant chemotherapy sensitive patients vs neoadjuvant chemotherapy resistant patients:
Sponsors
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Pathologically diagnosed breast cancer, women aged 18-75 years 2) The clinical stage is cT1-4N1-3M0 3) HR positive and HER2 negative. The positive threshold of ER, PR immunohistochemical test (IHC) is set to =1%, HER2 IHC 0-1 + or IHC 2+ and FISH test is negative; the expression level of Ki67 in tumor tissue is known before treatment, and the tissue can be processed Perform other biological and molecular tests 4) Receive at least two cycles of neoadjuvant chemotherapy 5) Receive subsequent mastectomy or breast-conserving surgery 6) ECOG score = 2 points 7) Blood picture, liver and kidney function are within the following allowable range (tested 7 days before the start of treatment): white blood cell (WBC) =3.0×10 ^ 9 / L or neutrophil (ANC) = 1.5×10 ^ 9 / L; Hemoglobin (HGB) = 80g / L; Platelets (PLT) = 100×10 ^ 9 / L; Liver transaminase (AST, ALT) <5.0 times the upper limit of the normal range; Total bilirubin (TBIL) <Normal range 2 times the upper limit; CREAT <1.5 times the upper limit of the normal range 8) Patients of childbearing age must take effective birth control measures
Exclusion criteria
Exclusion criteria: 1) Heart, lung, liver, kidney, hematopoietic function and abnormal reserve function are abnormal, and cannot tolerate surgical treatment and chemotherapy 2) The patient has cognitive impairment or is unable to adhere to long-term follow-up 3) History of other malignant tumors in the past 5 years 4) Pregnant or lactating women 5) Drug abuse, drug abuse, long-term alcohol addiction and sufferers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| full exon sequencing; | — |
Countries
China
Contacts
Public ContactChengjing
Outcome results
None listed